Here's What Analysts Are Forecasting For Krishna Institute of Medical Sciences Limited (NSE:KIMS) After Its Full-Year Results

Krishna Institute of Medical Sciences Limited (NSE:KIMS) came out with its yearly results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. It was a credible result overall, with revenues of ₹31b and statutory earnings per share of ₹9.61 both in line with analyst estimates, showing that Krishna Institute of Medical Sciences is executing in line with expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the most recent consensus for Krishna Institute of Medical Sciences from 13 analysts is for revenues of ₹39.8b in 2026. If met, it would imply a substantial 30% increase on its revenue over the past 12 months. Per-share earnings are expected to climb 18% to ₹11.36. In the lead-up to this report, the analysts had been modelling revenues of ₹39.4b and earnings per share (EPS) of ₹11.77 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a minor downgrade to their earnings per share forecasts.

Check out our latest analysis for Krishna Institute of Medical Sciences

It might be a surprise to learn that the consensus price target was broadly unchanged at ₹703, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Krishna Institute of Medical Sciences, with the most bullish analyst valuing it at ₹783 and the most bearish at ₹622 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Krishna Institute of Medical Sciences is an easy business to forecast or the the analysts are all using similar assumptions.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Krishna Institute of Medical Sciences' rate of growth is expected to accelerate meaningfully, with the forecast 30% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 19% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 18% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Krishna Institute of Medical Sciences to grow faster than the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Krishna Institute of Medical Sciences. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Krishna Institute of Medical Sciences going out to 2028, and you can see them free on our platform here.

It is also worth noting that we have found 2 warning signs for Krishna Institute of Medical Sciences (1 is significant!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.